Akiram Therapeutics: First clinical results from AKIR001 to be presented at EANM 2026

Conference177Lu-AKIR001Positive

AI Analysis

Summary

Akiram Therapeutics announces first clinical results from its Phase I trial of 177Lu-AKIR001 will be presented at EANM 2026 Congress in Vienna in October. The presentation represents an important milestone for the Swedish clinical-stage biotech company specializing in molecular radiotherapy.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First clinical data presentation from Phase I trial

Importance:5/10

Sentiment:

0.50

molecular radiotherapylead candidateclinical dataSwedish biotech

Related Companies

$MOLN $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Pharma on October 13, 2026 5:54 AM

Read Original